In Brief: New Warning for Injectable Medroxyprogesterone
Abstract
The FDA now requires that product labels for the long-acting injectable progestin contraceptive medroxyprogesterone acetate (MPA; Depo-Provera CI, and generics; Depo-SubQ Provera 104) include a warning about the risk of meningioma associated with its use.
Fields of Study & Subjects
Migraine and Headache Studies
Meningioma and schwannoma management
Reproductive Health and Contraception
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Publisher
- The Medical Letter, Inc.
- Volume
- 68
- Issue
- 1747
- Pages
- 24–24
- Publication date
- 2 February 2026
- Language
- EN